Citadel Advisors
XFOR icon

Citadel Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Citadel Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,727
Closed -$69K – 15393
2025
Q1 		$69K Buy
9,727
+4,210
+76% +$58K ﹤0.01% 11939
2024
Q4 		$121K Buy
5,517
+2,964
+116% +$47.2K ﹤0.01% 11165
2024
Q3 		$51.3K Buy
2,553
+1,736
+212% +$36.2K ﹤0.01% 11884
2024
Q2 		$14.2K Sell
817
-776
-49% -$25.4K ﹤0.01% 12898
2024
Q1 		$66.4K Buy
1,593
+1,143
+254% +$31.8K ﹤0.01% 11881
2023
Q4 		$11.3K Sell
450
-1,587
-78% -$38.6K ﹤0.01% 13049
2023
Q3 		$66.6K Sell
2,037
-5,030
-71% -$219K ﹤0.01% 11389
2023
Q2 		$411K Buy
7,067
+5,790
+453% +$298K ﹤0.01% 8355
2023
Q1 		$33.3K Sell
1,277
-233
-15% -$6.83K ﹤0.01% 12626
2022
Q4 		$45K Buy
1,510
+650
+76% +$30.8K ﹤0.01% 12265
2022
Q3 		$44K Buy
860
+37
+4% +$1.28K ﹤0.01% 11721
2022
Q2 		$24K Buy
823
+120
+17% +$4.57K ﹤0.01% 12329
2022
Q1 		$37K Buy
703
+56
+9% +$3.21K ﹤0.01% 12991
2021
Q4 		$44K Sell
647
-76
-11% -$9.61K ﹤0.01% 13320
2021
Q3 		$115K Sell
723
-50
-6% -$8.23K ﹤0.01% 12698
2021
Q2 		$151K Buy
+773
New +$194K ﹤0.01% 12498

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's XFOR Position: Q1 2026 in Review

Citadel Advisors sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 128,675 shares — an estimated $515K sold.

Citadel Advisors first reported a position in XFOR in Q1 2020 and held it in 14 quarters. The position peaked at $5.96M in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Citadel Advisors reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 128,675 X4 Pharmaceuticals shares in Q1 2026, an estimated $515K.
  • Citadel Advisors first reported a position in X4 Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Citadel Advisors's X4 Pharmaceuticals position peaked at $5.96M in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.